Video Corner
Video Corner
Watch Our Webcasts on YouTube
On Immunic‘s YouTube channel, you can watch our latest webcasts and conference calls, including public update and earnings calls, presentations from scientific and medical events, and updates on our clinical development programs.
2025
2024

Immunic, Inc. Q3 2024 Earnings Call Recording

Immunic ENSURE Program: Positive Outcome Interim Futility Analysis Recording

Immunic MS RnD Day New York City Recording

Immunic, Inc. Q2 2024 Earnings Call Recording

Immunic, Inc. Q1 2024 Earnings Call Recording

Immunic MS R&D Day San Francisco Recording

Immunic, Inc. Q4 and Year End 2023 Earnings Call Recording
2023

Immunic, Inc. Q3 2023 Earnings Call Recording

Immunic Vidofludimus Calcium CALLIPER Interim Data Recording

Immunic, Inc. Q2 2023 Earnings Call Recording

Immunic Celiac Disease KOL Roundtable Recording

Immunic, Inc. Q1 2023 Earnings Call Recording

Immunic IMU-856 Celiac Disease Phase 1b Data Recording

Immunic CALDOSE-1 Maintenance Data of Vidofludimus Calcium in UC and Pipeline Update Recording

Immunic, Inc. Q4 2022 Earnings Call Recording

Immunic Celiac Disease R&D Webcast Recording
2022

Immunic Multiple Sclerosis R&D Webcast Recording

Immunic, Inc. Q3 2022 Earnings Call Recording

Immunic, Inc. IMU-856 Phase 1 SAD MAD Data Healthy Human Subjects Webcast Recording

Immunic, Inc. Q2 2022 Earnings Call Recording

8th Joint ACTRIMS-ECTRIMS Meeting: Poster Presentation Dr. Robert Fox

Immunic CALDOSE-1 Phase 2 Top-Line Data in Ulcerative Colitis and Corporate Update Webcast Recording

Immunic Company Presentation @ BioEquity Europe 2022

Immunic, Inc. Q1 2022 Earnings Call Recording
2021
Watch Our Video Interviews on Proactive Investors
Proactive Investors is a financial news platform that delivers business and finance news to a global investment audience. Via the following links, you can watch our latest video and audio interviews with Immunic’s management team members.
2025

Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data

Immunic’s IMU-856 shows promise for obesity treatment

Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science

Immunic CEO on key MS trial data coming in April

Immunic COO Jason Tardio discusses key 2024 highlights, 2025 milestones
2024

Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead

Immunic CSO discusses breaking the IBD stigma to mark Crohn’s and Colitis Awareness Week

Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal

Immunic CEO details progress following productive third quarter

Immunic’s Jessica Breu talks BIO-Europe & MS research advancements

Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials

Immunic CMO on key ECTRIMS highlights and MS research

Immunic Thearapeutics Presents Advanced MS Treatment Data at Global Conference

Immunic CEO discusses New York MS R&D Day, potential of vidofludimus calcium and MS studies

Immunic says first patient enrolled in investigator-sponsored post-COVID syndrome trial

Immunic CEO discusses Q2 results & MS trials update

Immunic CSO outlines progress with MS therapies to mark World Brain Day

Immunic CEO Daniel Vitt discusses rise in autoimmune diseases and MS treatments

Immunic Inc. CEO Daniel Vitt Highlights Advances in MS Treatment on World MS Day

Immunic CMO discusses role of clinical trials in biotech development for Clinical Trials Day

Immunic chief medical officer discusses promising treatments to mark World IBD Day

Immunic highlights IMU-856 gastrointestinal candidate to mark International Celiac Day

Immunic CEO Dr Daniel Vitt discusses key Q1 advances and upcoming milestones

Immunic CEO Dr Daniel Vitt provides hope for sufferers during Celiac Awareness Month

Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal

Immunic CMO details programs aimed at alleviating multiple sclerosis during UK’s MS Awareness Week

Immunic secures key patent, boosting MS drug exclusivity and global IP strategy

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024

Immunic reports successful 2023 and prepares for key 2025 milestones

Immunic CSO highlights her role ahead of International Day of Women and Girls in Science

Immunic says $240M financing shows confidence in Phase 2 CALLIPER study as it targets unmet MS needs

Immunic kicks off 2024 with massive fundraise
2023

Immunic focusing on business development during Q4

Immunic CSO hails “great” progress with MS program

Immunic “super excited” about latest PMS trial data

Immunic CEO hails “great day” after completing IMU-838 phase 2 trial enrolment

Immunic CEO says Q2 results “couldn’t be better”

Immunic Inc eyeing “big step” for multiple sclerosis patients

Immunic Therapeutics shares IMU-856 mode of action and target for gastrointestinal diseases

Immunic ultimately hoping to “offer patients a new kind of treatment” for multiple sclerosis

Immunic says preclinical data for vidofludimus calcium is a milestone for its lead MS program

Immunic Inc set to bring relief with encouraging results

Immunic IMU-856 trial data “clearly goes beyond” initial expectations

Immunic gets a “positive surprise” from lead asset trial

Immunic Therapeutics taking a “unique approach” in biopharma
Immunic presents at ACTRIMS forum as it awaits key CALLIPER MS trial data
https://www.proactiveinvestors.com/companies/news/1067439/immunic-presents-at-actrims-forum-as-it-awaits-key-calliper-ms-trial-data.html
Immunic’s IMU-856 shows promise for obesity treatment
https://www.proactiveinvestors.com/companies/news/1066609/immunic-s-imu-856-shows-promise-for-obesity-treatment-1066609.html
Immunic / IMU-856: Dose-Dependent Increase of GLP-1 in Patients
https://www.youtube.com/watch?v=QhdsdAFUL6w
Breaking Barriers: Immunic CSO marks International Day of Women and Girls in Science
https://www.proactiveinvestors.com/companies/news/1066037/breaking-barriers-immunic-cso-marks-international-day-of-women-and-girls-in-science-1066037.html
Immunic CEO on key MS trial data coming in April
https://www.proactiveinvestors.com/companies/news/1065904/immunic-ceo-on-key-ms-trial-data-coming-in-april-1065904.html
Immunic COO Jason Tardio discusses key 2024 highlights, 2025 milestones
https://www.proactiveinvestors.com/companies/news/1063815/immunic-coo-jason-tardio-discusses-key-2024-highlights-2025-milestones-1063815.html
Immunic CEO Dr Daniel Vitt on successful 2024, with more to come in the year ahead
https://www.proactiveinvestors.com/companies/news/1062783/immunic-ceo-dr-daniel-vitt-on-successful-2024-with-more-to-come-in-the-year-ahead-1062783.html
Immunic CSO discusses breaking the IBD stigma to mark Crohn’s and Colitis Awareness Week
https://www.proactiveinvestors.com/companies/news/1061862/immunic-cso-discusses-breaking-the-ibd-stigma-to-mark-crohn-s-and-colitis-awareness-week-1061862.html
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal
https://www.proactiveinvestors.co.uk/companies/news/1060545/immunic-announces-publication-of-imu-856-phase-1-trial-data-in-peer-reviewed-journal-1060545.html
Immunic, Inc. Q3 2024 Earnings Call Recording
https://www.youtube.com/watch?v=Jg0OrheALEQ